MedTrace Logo

Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants

NCT07419698 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-02-19

No results posted yet for this study

Summary

A This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial. It aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single administration of JMT206 Injection in healthy participants.

Conditions

  • Healthy Participants

Interventions

BIOLOGICAL

JMT206

Subcutaneous injection, single dose.

DRUG

Placebo

Subcutaneous injection, single dose.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2026-09-01
Completion
2026-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07419698 on ClinicalTrials.gov